CA-FORESCOUT-TECH
6.6.2022 15:02:12 CEST | Business Wire | Press release
Forescout Technologies, Inc. , the global leader in automated cybersecurity, today announced that it has signed a definitive agreement to acquire Cysiv , a cybersecurity innovator that uses its cloud platform to improve detection and response of true threats. With this acquisition, Forescout will leverage Cysiv’s threat detection engine to analyze a wealth of asset and network communications data automatically collected by Forescout’s platform. This comprehensive data across IT, IoT, OT and IoMT devices, as well as other essential data sources, enables better true threat detection and response so customers can operate more securely and efficiently. Upon the close of the acquisition, Cysiv will join Forescout.
“Organizations need to be able to reduce the billions of data points on their networks to a handful of actionable true threats – automatically. Together with Cysiv, Forescout will provide customers with the most powerful platform for automated cybersecurity across their digital terrains,” said Wael Mohamed, CEO of Forescout. “Upon close, the acquisition will help our customers leverage actionable threat intelligence from comprehensive data collected by Forescout and analyzed by Cysiv. We will receive far more than just great technology in this acquisition. The Cysiv team is exceptional, and our two organizations are highly complementary.”
Today, organizations are faced with the immense pressure to secure their networks. CIOs and CISOs have experienced rapid growth in the volume and diversity of managed and unmanaged devices, including IoT devices, that has given rise to increased risks and cybersecurity threats, coinciding with a drop in available cybersecurity resources. With the rapid adoption of cloud, and a cloud-first mindset that’s been accelerated by the work-from-anywhere shift of the past two years, enterprises are particularly concerned with managing threats to these fluid threat environments. This has resulted in organizations not being able to effectively manage the detection, investigation, escalation and response of true threats, particularly as the threat landscape and unmanaged device landscape have become more complex.
Existing solutions for threat detection and response, such as EDR, require the use of agents on managed devices. This means that organizations dependent on an agent-based approach for threat detection and response are not able to look for threats coming from the majority of their connected devices, particularly critical assets like IoT, IoMT and OT.
For over a decade, Forescout’s ability to deeply integrate into the fabric of customers’ networks has enabled it to collect real-time data for all connected assets and users, together with the communications among those assets and users. Customers have been asking Forescout to leverage this comprehensive data to provide greater insight into threats for all types of assets and to enable faster, more automated response and remediation.
“We have always been on a mission to provide better threat detection and faster response,” said Partha Panda, CEO and co-founder of Cysiv. “After successfully partnering together for the last year, we are thrilled to join Forescout as we continue on the next stage of our journey. The combination of Forescout and Cysiv will provide organizations with best-in-class threat detection together with automated incident prioritization and automated response.”
The acquisition is expected to close in July, 2022, subject to the satisfaction of closing conditions and receipt of applicable regulatory approvals and comes on the heels of its acquisition of CyberMDX which further strengthens Forescout’s industry-leading IT, IoT and OT device coverage with IoMT expertise.
About Forescout
Forescout Technologies, Inc. delivers cybersecurity automation across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types. The Forescout Continuum Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com
Managing cyber risk, together.
© 2022 Forescout Technologies, Inc. All rights reserved. Forescout Technologies, Inc. is a Delaware corporation. A list of our trademarks and patents can be found at https://www.forescout.com/company/legal/intellectual-property-patents-trademarks . Other brands, products, or service names may be trademarks or service marks of their respective owners.
About Cysiv
Cysiv security operations center (SOC)-as-a-service provides enterprises with better detection and faster response of true threats. We do this by uniquely combining our cloud-native next generation SIEM, with a data-centric approach and a team of experts that operate as a seamless extension of your SOC. All of this is delivered as a subscription-based service, with predictable and flexible pricing, that can be operational in weeks. Cysiv’s modern approach to threat detection and response helps reduce risk, ensure compliance, and improve the efficiency, effectiveness and maturity of your security operations. To learn more, visit www.cysiv.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005321/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
